The focus of this program will be to provide scientific updates and management tools to improve atopic dermatitis (AD) disease control, treatment adherence, and quality of life. AD in adults is often unrecognized, although evidence suggests this condition is more common and complex than previously thought due to differing phenotypes and potential endotypes that can have significant therapeutic implications. We will explore how utilization of all these factors in a targeted treatment plan can result in better outcomes for lifelong disease management. Research into the underlying mechanisms of AD has led to development of targeted therapies that have the potential to dramatically change the treatment paradigm.
We will first review current American Academy of Dermatology recommendations for the management of moderate-to-severe AD and then discuss how the newly-approved therapies can be integrated into the treatment decision-making process. Besides a multifactorial etiology, AD is also associated with serious comorbidities in adults, most notably a higher incidence of cardiovascular disease and depression.
A multidisciplinary approach to AD will be presented to address the biological, psychological, behavioral, and dietary factors that affect AD and the supportive skills and education patients need to manage and cope with this pervasive condition. We will include a patient case in the program for discussion of how to apply the data to real-world multidisciplinary approaches for optimal patient care.
Instructions for This Activity and Receiving Credit
This program is directed toward community dermatologists, allergists, immunologists, rheumatologists, and primary care physicians. Fellows, nurse practitioners, physician assistants, researchers, and other health care professionals interested in the treatment or management of AD are also invited to participate.
Upon completion of this program, participants will be able to:
Peter A. Lio, MD
Clinical Assistant Professor of Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Disclosure: Grant/Research Support: AOBIOME, La Fondation pour la Dermatite Atopique; Consultant: Anacor/Pfizer, AOBiome, Galderma, IntraDerm, Johnson & Johnson, La Roche-Posay/L’Oreal, Menlo Therapeutics, Pierre Fabre Dermatologie, Realm Therapeutics, Regeneron/Sanofi, Theraplex, Valeant; Speaker's Bureau: Regeneron/ Sanofi, Anacor/ Pfizer, Pierre Fabre Dermatologie, Valeant, La Roche- Posay/L’Oreal; Stock/Shareholder: Odeza, Modernizing Medicine
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
This program is jointly provided by Global Education Group and Physicians’ Education Resource®, LLC. AMA PRA Category 1 Credit™ is provided by Global Education Group.
This program has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Physicians’ Education Resource®, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this live program for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the program.
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational program for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the program.
This program has been planned and implemented in accordance with the accreditation standards of the American Association of Nurse Practitioners (AANP) through joint providership of Global Education Group and PER®. Global Education Group is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number: 1561024. This program is approved for 1.0 contact hour(s) which includes 0.0 hour(s) of pharmacology.
Activity ID #2464L.
This program was planned in accordance with AANP CE standards and policies.
For information about the approval and accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
There is no fee for this educational program.
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this program to disclose any real or apparent conflict of interest they may have as related to the content of this program. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
This CME/CE program may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE program is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or of the company that provided commercial support for this program.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this program is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this program should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The following contributors have no relevant financial relationships with commercial interests to disclose.
Physicians’ Education Resource®, LLC (PER®)
Planning Staff—David Heckard; Maryjo Dixon, RPh; Gloria Lauria and Kate Bowen.
Global Education Group
Kristen Delisi, NP; Lindsay Borvansky; Ashley Marostica, RN, MSN; Andrea Funk; and Liddy Knight
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018